Ethris mRNA LNP Platform news

News

Press Releases

ETHRIS INITIATES FIRST-IN-HUMAN DOSING IN PHASE 1 STUDY FOR ETH47 FOR THE TREATMENT OF VIRUS-INDUCED ASTHMA


Munich, Germany, December 18, 2023Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced the dosing of the first healthy participant in its first-in-human study of lead candidate ETH47, which was developed using Ethris’ Stabilized Non-Immunogenic mRNA (SNIM®RNA) platform and encodes for type III interferon (IFN) that plays a vital role in early antiviral response. ETH47 was also designed to be administered locally to the lung through inhalation or nasal spray using the company’s proprietary Stabilized NanoParticle (SNaP) LNP platform. The Phase 1 study will primarily evaluate ETH47’s safety and tolerability in healthy participants. The program, although initially focused on virus-induced asthma, has the potential to be applied for pandemic preparedness against influenza and SARS-CoV-2 due to its broad applicability. 

ETHRIS ANNOUNCES APPROVAL OF PHASE I CLINICAL STUDY FOR ETH47, A FIRST-IN-CLASS INHALED mRNA FOR RESPIRATORY VIRAL INFECTIONS

Munich, Germany, November 28, 2023Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that it has received approval from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with a Phase 1 clinical trial for its inhaled mRNA program, ETH47, in healthy participants for the treatment and prophylaxis of respiratory viral infections. The authorization follows Ethris’ submission of a Clinical Trial Authorization (CTA) application to the MHRA in June 2023. The Phase 1 study is expected to commence in the U.K already in December 2023.

ETHRIS AND HEQET THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP RNA-BASED THERAPEUTICS FOR HEART ATTACK AND HEART FAILURE

Munich, Germany, and London, United Kingdom, November 13, 2023Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Heqet Therapeutics, a biotechnology spin-out company from King’s College London active in the field of regenerative medicine, today announced a collaboration agreement to harness the potential of ncRNA for heart tissue regeneration following acute myocardial infarction (heart attack) and in heart failure. Under the terms of the agreement, Heqet Therapeutics will lead the development of the program, while Ethris will provide its proprietary Stabilized NanoParticle (SNaP) LNP platform to deliver ncRNA payloads to the heart tissue. 

ETHRIS JOINS ALLIANCE FOR mRNA MEDICINES AS A FOUNDING MEMBER

Munich, Germany, November 1, 2023 - Ethris GmbH, a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, announced today it will be a founding member of a new global organization called Alliance for mRNA Medicines (AMM). 

DIOSYNVAX AND ETHRIS PUBLISH PRECLINICAL PROOF OF CONCEPT FOR THEIR BROADLY PROTECTIVE VACCINE TECHNOLOGIES IN NATURE BIOMEDICAL ENGINEERING

Munich, Germany and Cambridge, United Kingdom, September 25, 2023

Ethris and DIOSynVax, a Cambridge UK based clinical stage biotech spinout specialized in the development of multi-valent vaccine antigen payloads (VAPs), announced today the publication of preclinical proof of concept results for each of their platform technologies in Nature Biomedical Engineering.

ETHRIS ANNOUNCES $42 MILLION COLLABORATION WITH DIOSYNVAX AND CEPI TO DEVELOP A BROADLY PROTECTIVE MRNA VACCINE AGAINST BETACORONAVIRUSES

Munich, Germany, December 21, 2022

Ethris announced today a collaboration with UK-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of Betacoronaviruses utilizing the company’s highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilisation platforms.

ETHRIS ANNOUNCES €15 MILLION INVESTMENT FROM CIPLA AND INITIATION OF A STRATEGIC COLLABORATION

Mumbai, India and Munich, Germany: December 29, 2022

Ethris announced today that it has signed a definitive agreement with Cipla for an equity investment of EUR 15 million in Ethris.

ETHRIS RAISES $26.3 MILLION SERIES B TO ADVANCE PIPELINE OF MRNA-BASED THERAPEURICS FOR RESPIRATORY DISEASES

Munich, Germany, February 1, 2022

Ethris GmbH, a leading biotechnology company pioneering transformative messenger RNA (mRNA) therapeutics, announced today that it has raised $26.3 Million (€23.3 Million) in a Series B financing round led by Laureus Capital.

ETHRIS RECEIVES “MOST INNOVATIVE PRODUCT TOP 3” AWARD FOR COVID-19 THERAPEUTIC CANDIDATE AT 22ND PHARMA TREND IMAGE & INNOVATION AWARD

Munich, Germany, September 15, 2021

Ethris GmbH announced today that its lead COVID-19 therapeutic candidate, ETH47, has been awarded “The Most Innovative Product Top 3” in the category of Leap Innovations at the Pharma Trend Image & Innovation Awards 2021.

ETHRIS ANNOUNCES POSITIVE SCIENTIFIC REVIEW OF ITS MRNA-BASED COVID-19 THERAPEUTIC PROGRAM APPLICATION TO BAVARIAN BAYTHERAPIE2020 GRANT PROGRAM

Munich, Germany, March 30, 2021

Funding will advance Ethris’ development of an mRNA-based therapeutic to treat SARS-CoV-2 and its variants

NEURIMMUNE AND ETHRIS SIGN COLLABORATION AGREEMENT TO RAPIDLY DEVELOP INHALED MRNA-BASED ANTIBODY THERAPY FOR THE TREATMENT OF COVID-19

Zurich, Switzerland and Munich, Germany, April 1, 2020

Neurimmune AG and Ethris GmbH announced today an exclusive partnership to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of Covid-19.

ETHRIS ANNOUNCES EXPANSION OF LEADERSHIP TEAM

Munich, Germany, June 3, 2019

Ethris announced  the expansion of the company’s leadership team by the addition of Thomas Langenickel, M.D. in the role of Chief Medical Officer. Dr. Langenickel joined Ethris from Novartis AG, where he was Executive Director and Head of Respiratory Profiling within the Translational Medicine Group.

ETHRIS AND MUNSTER UNIVERSITY HOSPITAL RECEIVE ZIM GRANT FOR RARE PULMONARY DISEASE RESEARCH

Munich, Germany, October 1, 2019

Ethris’ existing collaboration with the Munster University Hospital has been awarded a research grant by the Central Innovation Program for SMEs (ZIM). The funding will help accelerate the joint research project in primary ciliary dyskinesia (PCD), including evaluation of ETH42, a first-in-class SNIM®RNA product in preclinical development.

ETHRIS ANNOUNCES LEADERSHIP TEAM UPDATE

Munich, Germany, December 07, 2018

Ethris adapted the responsibilities among its leadership team to position the company for the next phase of its development. As a result, Dr. Gita Dittmar took on the role as Chief Executive Officer, PD Dr. Carsten Rudolph became Chief Scientific Officer and Prof. Dr. Christian Plank became Chief Technology Officer.

ETHRIS ENTERS STRATEGIC COLLABORATION WITH ASTRAZENECA AND MEDIMMUNE

Munich, Germany, August 21, 2017

Ethris  and AstraZeneca signed a five-year strategic research collaboration that is focused on developing new stabilized non-immunogenic modified RNA therapies for respiratory diseases using Ethris’ proprietary SNIM®RNA technology. Ethris received €25 million upfront plus research funding and is eligible for future research and development milestones, including sales related royalties upon commercialization.

ETHRIS ADDS THREE NEW MEMBERS TO ITS BOARD OF DIRECTORS

Munich, Germany, July 19, 2016

Ethris announced the addition of Dr. Leon Chen, Dr. Thomas Chalberg, and Justin Duckworth to the Ethris Board of Directors to support the next stage of the company’s development.

ETHRIS PUBLISHES PRECLINICAL DATA ON MUSCULOSKELETAL REGENERATION

Munich, Germany, March 21, 2016

Ethris announced the publication of a research paper in the peer-reviewed journal “Biomaterials” that underlines the broad therapeutic potential of the company’s proprietary mRNA transcript therapy platform. The paper demonstrates that a modified mRNA construct based on Ethris’ technology coding for the human growth factor BMP-2 (bone morphogenetic protein-2) can induce bone regeneration in three different settings including an established in-vivo model for bone healing.

Partnering Statements

Ethris and Partners Launch EU Research Project cmRNABone to Develop a Novel mRNA Transcript Therapy for Bone Regeneration

Munich, Germany, February 11th, 2020

Ethris has joined the cmRNAbone consortium of 11 European partners working to develop chemically modified RNAs and a specific vector delivery system as a novel bone regenerative therapy for trauma and osteoporosis patients. The partners will receive EUR 6.3 million funding from the European Union’s Horizon 2020 Framework Program.

Ethris and Partners Receive Horizon 2020 Grant to Explore New Therapeutic Paradigm in Cardiac Regeneration

Munich, Germany, October 30th, 2019

Ethris has joined the cmRNAbone consortium of 11 European partners working to develop chemically modified RNAs and a specific vector delivery system as a novel bone regenerative therapy for trauma and osteoporosis patients. The partners will receive EUR 6.3 million funding from the European Union’s Horizon 2020 Framework Program.

Ethris and Partners Receive Eurostars Grant for the Development of New mRNA Therapeutics for Osteoarthritis

Munich, Germany, July 24th, 2019

Ethris and its partners 20Med Therapeutics, the AO Research Institute Davos and Paracelsus Medical University have received a Eurostars grant to be used to further the development of a novel approach to treating osteoarthritis. The Eurostars program is managed by the EUREKA organization and is supported by the European Union under the Horizon 2020 Framework Program.

Go to Partner Press Release

Ethris’ Collaborators at LMU München Children’s Hospital Publish Paper in Nature Nanotechnology

Munich, Germany, January 28th, 2019

Ethris scientific partners have published a paper on non-viral gene delivery using a polyoxamine-based co-polymer nanoparticle and the impact on long-term restoration of the CFTR gene in in vivo models of cystic fibrosis. We are proud to have contributed our SNIM RNA tech to enable these results.

Read more in "Nature Nanotechnology"